Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax(TM) Treatment
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Nelipepimut-S (Primary) ; Sargramostim
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms PRESENT
- Sponsors Galena Biopharma
- 31 Aug 2018 Biomarkers information updated
- 09 Nov 2016 According to a Galena Biopharma media release, management will present the top-line data from the trial and its assessment of the results in conference call.
- 09 Aug 2016 Company has initiated an investigation into the causes of the the Independent Data Monitoring Committee (IDMC) recommendation to stop the trial, according to a Galena Biopharma media release.